A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial

Esposito, Cristina; Garzarella, Emanuele Ugo; Bocchino, Bruno; D'Avino, Maria; Caruso, Giuseppe; Buonomo, Antonio Riccardo; Sacchi, Roberto; Galeotti, Fabio; Tenore, Gian Carlo; Zaccaria, Vincenzo; Daglia, Maria

doi:10.1016/j.phymed.2020.153368

Cited by 29 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty studies involving 5,166 subjects (flavonoids group: 2636; control group: 2530) were included. Five eligible studies ( 20 – 24 ) investigated the efficacy of flavonoids in the common cold, 4 ( 25 – 28 ) in influenza, 5 ( 29 – 33 ) in COVID−19, 3 ( 34 – 36 ) in acute non-streptococcal tonsillopharyngitis, 1 ( 37 ) in acute rhinosinusitis, 7 ( 38 – 44 ) in acute bronchitis, 1 ( 45 ) in bronchial pneumonia, and 4 ( 46 – 49 ) in upper respiratory tract infections. In common cold, 5 RCTs with 503 patients were involved.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the basis of missing outcome data, 4 (13.3%) studies ( 27 , 35 , 36 , 49 ) were considered as high risk for more than 5% of missing outcome data which could have made a negative impact on the estimated effect of the intervention. Regarding the bias of measurement of the outcome was rated at high risk in 4 (13.3%) RCTs ( 30 , 46 – 48 ) for that the outcome assessors were aware of the interventions. Regarding the bias of selection of the reported result, 10 (33.3%) RCTs ( 24 , 25 , 27 , 28 , 36 , 38 , 43 , 45 , 48 , 49 ) were rated at some concerns for no protocols or registrations.…”

Section: Resultsmentioning

confidence: 99%

“…Four eligible RCTs ( 46 – 49 ) investigated the efficacy and safety of flavonoids in upper respiratory tract infections.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Yao

Zhang

Wang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThis meta-analysis aimed to investigate the efficacy and safety of flavonoids in treating viral acute respiratory tract infections (ARTIs).MethodsRandomized controlled trials (RCTs) were entered into meta-analyses performed separately for each indication. Efficacy analyses were based on changes in disease-specific symptom scores. Safety was analyzed based on the pooled data from all eligible trials, by comparing the incidence of adverse events between flavonoids and the control.ResultsIn this study, thirty RCTs (n = 5,166) were included. In common cold, results showed that the flavonoids group decreased total cold intensity score (CIS), the sum of sum of symptom intensity differences (SSID) of CIS, and duration of inability to work vs. the control group. In influenza, the flavonoids group improved the visual analog scores for symptoms. In COVID−19, the flavonoids group decreased the time taken for alleviation of symptoms, time taken for SARS-CoV−2 RT-PCR clearance, the RT-PCR positive subjects at day 7, time to achievement of the normal status of symptoms, patients needed oxygen, patients hospitalized and requiring mechanical ventilation, patients in ICU, days of hospitalization, and mortality vs. the control group. In acute non-streptococcal tonsillopharyngitis, the flavonoids group decreased the tonsillitis severity score (TSS) on day 7. In acute rhinosinusitis, the flavonoids group decreased the sinusitis severity score (SSS) on day 7, days off work, and duration of illness. In acute bronchitis, the flavonoids group decreased the bronchitis severity score (BSS) on day 7, days off work, and duration of illness. In bronchial pneumonia, the flavonoids group decreased the time to symptoms disappearance, the level of interleukin−6 (IL−6), interleukin−8 (IL−8), and tumor necrosis factor-α (TNF-α). In upper respiratory tract infections, the flavonoids group decreased total CIS on day 7 and increased the improvement rate of symptoms. Furthermore, the results of the incidence of adverse reactions did not differ between the flavonoids and the control group.ConclusionResults from this systematic review and meta-analysis suggested that flavonoids were efficacious and safe in treating viral ARTIs including the common cold, influenza, COVID−19, acute non-streptococcal tonsillopharyngitis, acute rhinosinusitis, acute bronchitis, bronchial pneumonia, and upper respiratory tract infections. However, uncertainty remains because there were few RCTs per type of ARTI and many of the RCTs were small and of low quality with a substantial risk of bias. Given the limitations, we suggest that the conclusions need to be confirmed on a larger scale with more detailed instructions in future studies.Systematic Review Registration:inplasy.com/inplasy-2021-8-0107/, identifier: INPLASY20218010

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Yao

Zhang

Wang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Its color varies from yellowish green to dark brown, and odor from odorless to aromatic, and depends on its botanical source, origin of place, and bee characteristics such as strain and age [ 1 ]. Besides the structural and functional attributes of propolis for bees [ 2 ], it has been reported to possess a variety of therapeutic potentials for human use [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ] since ancient times. There are mainly two kinds of propolis known that differ in their constituents: New Zealand propolis possesses CAPE (Caffeic Acid Phenethyl Ester) and Brazilian green propolis that possesses Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid, ARC) as pre-dominant bioactive compounds [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular Insights into the Antistress Potentials of Brazilian Green Propolis Extract and Its Constituent Artepillin C

Kaul

Kuthethur

Ishida³

et al. 2021

Molecules

View full text Add to dashboard Cite

Propolis, also known as bee-glue, is a resinous substance produced by honeybees from materials collected from plants they visit. It contains mixtures of wax and bee enzymes and is used by bees as a building material in their hives and by humans for different purposes in traditional healthcare practices. Although the composition of propolis has been shown to depend on its geographic location, climatic zone, and local flora; two largely studied types of propolis: (i) New Zealand and (ii) Brazilian green propolis have been shown to possess Caffeic Acid Phenethyl Ester (CAPE) and Artepillin C (ARC) as the main bioactive constituents, respectively. We have earlier reported that CAPE and ARC possess anticancer activities, mediated by abrogation of mortalin-p53 complex and reactivation of p53 tumor suppressor function. Like CAPE, Artepillin C (ARC) and the supercritical extract of green propolis (GPSE) showed potent anticancer activity. In this study, we recruited low doses of GPSE and ARC (that did not affect either cancer cell proliferation or migration) to investigate their antistress potential using in vitro cell based assays. We report that both GPSE and ARC have the capability to disaggregate metal- and heat-induced aggregated proteins. Metal-induced aggregation of GFP was reduced by fourfold in GPSE- as well as ARC-treated cells. Similarly, whereas heat-induced misfolding of luciferase protein showed 80% loss of activity, the cells treated with either GPSE or ARC showed 60–80% recovery. Furthermore, we demonstrate their pro-hypoxia (marked by the upregulation of HIF-1α) and neuro-differentiation (marked by differentiation morphology and upregulation of expression of GFAP, β-tubulin III, and MAP2). Both GPSE and ARC also offered significant protection against oxidative stress and, hence, may be useful in the treatment of old age-related brain pathologies.

show abstract

“…In the clinical studies conducted, it is seen that propolis is an effective antiviral and antibacterial agent. In a double-blind, placebo-controlled clinical study conducted by Esposito et al, it has been shown that oral propolis supplementation improved the symptoms of mild upper respiratory tract infection without requiring pharmacological treatment (18).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals

Bilir¹,

guler²,

Koçak

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: No prophylactic treatment is available for individuals at high risk of developing COVID-19. This study, which was conducted between December 25, 2020 and January 25, 2021, is one of the first clinical studies to evaluate the efficacy of Anatolian propolis supplement against COVID-19. The aim was to obtain evidence on the prophylactic use of Anatolian propolis in individuals at high risk of developing COVID-19. Methods: This volunteer-based study was conducted in two centers. Study involved 209 healthcare professionals (physicians, nurses, medical secretaries) from Emergency Medicine Department of Medical Faculty of Ataturk University and Emergency Medicine Department of Rize Recep Tayyip Erdogan University. 209 participants meeting the study criteria were divided into two groups as experimental group and control group. The experimental group received 20 drops of BEE'O UP 30% Propolis Drops twice a day during a follow-up period of 1 month. The control group received no supplement but was followed up. Findings: The participants showing symptoms during the study and all the participants at the end the study were subjected to PCR testing. The evaluation of the results of PCR testing at the end of the study has shown that 14 participants from the control group and only 2 participants from the experimental group, who received Anatolian propolis supplement, were reported as positive cases. Interpretation: It has been found that a statistically significant protection was induced against COVID-19 infection in 98% of the experimental group, who received Anatolian propolis, compared to the control group.

show abstract

A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial

Cited by 29 publications

References 27 publications

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials

Molecular Insights into the Antistress Potentials of Brazilian Green Propolis Extract and Its Constituent Artepillin C

Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals

Contact Info

Product

Resources

About